Therapeutic idiotype vaccines in B lymphoproliferative diseases

Bibliography

• LYNCH RG, CRAFF RG, SIRISINHA S,SIMMS ES, EISEN HN: Myeloma proteins as tumor-specific transplantation antigens. Proc. Nati Acad. Sci. USA (1972) 69:1540–1544.
   PubMed Web of Science ®Google Scholar
• JORGENSEN T, GAUDERNACK G, HANNESTAD K: Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOP C315. Scand. Immunol. (1980) 11(1):29–35.
   PubMed Web of Science ®Google Scholar
• DALEY MJ, GEBEL HM, LYNCH RG: Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy.f Immunol (1978) 120(5):1620–1624.
   PubMed Web of Science ®Google Scholar
• BRIDGES SH: Participation of the humoral immune system in the myeloma-specific transplantation resistance. Immunol. (1978) 121(2):479–483.
   Web of Science ®Google Scholar
• FREEDMAN PM, AUTRY JR, TOKUDA S, WILLIAMS RC JR: Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein.' Natl. Cancer Inst. (1976) 56(4):735–740.
   Google Scholar
• SUGAI S, PALMER DW, TALAL N, WITZ IP: Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW Fl mice.' Exp. Med. (1974) 140(6):1547–1558.
   Google Scholar
• STEVENSON FK, GORDON J: Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. Immunol. (1983) 130(2):970–973.
   Web of Science ®Google Scholar
• GEORGE AJ, TUTT AL, STEVENSON FK: Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. I Immunol. (1987) 138(2):628–634.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, KITAMURA K, MALONEY DG, LEVY R: Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.' Immunol. (1987) 138(4):1289–1296.
   Google Scholar
• KWAK LW, YOUNG HA, PENNINGTON RW, WEEKS SD: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Nati Acad. Sci. USA (1996) 93:10972–10977.
   PubMed Web of Science ®Google Scholar
• KWAK LW, CAMPBELL MJ, CZERWINSKI DK, HART S, MILLER RA, LEVY R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl. I Med. (1992) 327:1209–1215.
   PubMed Web of Science ®Google Scholar
• HSU FJ, CASPAR CB, CZERWINSKI D et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood (1997) 89:3129–3135.
   PubMed Web of Science ®Google Scholar
• BENDANDI M, GOCKE CD, KOBRIN CB et al: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. (1999) 5:1171–1177.
   PubMed Web of Science ®Google Scholar
• NEELAPU SS, GAUSE BL, NIKCEVICH DA et al.: Phase III randomized trial of patient-specific vaccination for previously untreated follicular lymphoma patients in first complete remission: protocol summary and interim report. Clin. Lymphoma (2004) (In Press).
   Google Scholar
• BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245–252.
   PubMed Web of Science ®Google Scholar
• TIMMERMAN JM, CZERWINSKI DK, DAVIS TA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 99(5):1517–1526.
   PubMed Web of Science ®Google Scholar
• NEELAPU SS, BASKAR S, GAUSE BL et al.: Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. (2004) (Manuscript submitted).
   Google Scholar
• DIANZANI U, PILERI A, BOCCADORO M et al: Activated idiotype-reactive cells in suppressor/ cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood (1988) 72(3):1064–1068.
   PubMed Web of Science ®Google Scholar
• YI Q, OSTERBORG A, BERGENBRANT S, MELLSTEDT H, HOLM G, LEFVERT AK: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood (1995) 86(8):3043–3049.
   PubMed Web of Science ®Google Scholar
• YI Q, ERIKSSON I, HEW, HOLM G, MELLSTEDT H, OSTERBORG A: Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. Br. Haematol (1997) 96(2):338–345.
   PubMed Web of Science ®Google Scholar
• BOGEN B, MALISSEN B, HAAS W: Idiotype-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur: brimunol. (1986) 16(11):1373–1378.
   PubMed Web of Science ®Google Scholar
• LI Y, BENDANDI M, DENG Y et al.: Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood (2000) 96:2828–2833.
   PubMed Web of Science ®Google Scholar
• HAYASHI T, HIDESHIMA T, AKIYAMA M et al: Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood (2003) 102(4):1435–1442.
   PubMed Web of Science ®Google Scholar
• BERGENBRANT S, YI Q, OSTERBORG A et al.: Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br. Haematol (1996) 92(4)840–846.
   Google Scholar
• OSTERBORG A, YI Q, HENRIKSSON L et al.: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood(1998) 91(7):2459–2466.
   PubMed Web of Science ®Google Scholar
• MASSAIA M, BORRIONE P, BATTAGLIO S et al: Id vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood (1999) 94:673–683.
   PubMed Web of Science ®Google Scholar
• COSCIA M, MARIANI S, BATTAGLIO S et al: Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia (2004) 18(1):139–145.
   PubMed Web of Science ®Google Scholar
• REICHARDT VL, OKADA CY, LISO A et al: Id vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood (1999) 93(7):2411–2419.
   PubMed Web of Science ®Google Scholar
• YI Q, DESIKAN R, BARLOGIE B, MUNSHI N: Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br. Haematol (2002) 117:297–305.
   PubMed Web of Science ®Google Scholar
• TITZER S, CHRISTENSEN 0, MANZKE 0 et al.: Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br. Haematol (2000) 108:805–816.
   Google Scholar
• GONG J, KOIDO S, CHEN D et al: Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood (2002) 99:2512–2517.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN T, HANSSON L, OSTERBORG A, JOHNSEN HE, MELLSTEDT H: Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood (2003) 101 (11):4607–4610.
   PubMed Web of Science ®Google Scholar
• ANDERSON KC, KYLE RA, DALTON WS et al.: Multiple myeloma: new insights and therapeutic approaches. Hematology (American Socie0, of Hematology Education Program) (2000):146–165.
   Google Scholar
• KAY NE, LEONG TL, BONE N et al: Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group Phase III trial for newly diagnosed multiple myeloma patients. Blood (2001) 98(1) :23–28.
   PubMed Web of Science ®Google Scholar
• KAY NE, LEONG T, KYLE RA et al: Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group Phase III E9486 clinical trial. Blood (1997) 90(1):340–345.
   PubMed Web of Science ®Google Scholar
• MASSAIA M, BORRIONE P, ATTISANO C et al.: Dysregulated Fas and Bc1-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood (1995) 85(12):3679–3687.
   PubMed Web of Science ®Google Scholar
• RATTA M, FAGNONI F, CURTI A et al:Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood (2002) 100(1):230–237.
   PubMed Web of Science ®Google Scholar
• KWAK LW, NEELAPU S, BISHOP MR: Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin. Oncol (2004) 31(1):37–46.
   PubMed Web of Science ®Google Scholar
• KING CA, SPELLERBERG MB, ZHU D et al.: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. (1998) 4(11):1281–1286.
   PubMed Web of Science ®Google Scholar
• SAVELYEVA N, MUNDAY R, SPELLERBERG MB, LOMONOSSOFF GP, STEVENSON FK: Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat. Biotechnol (2001) 19(8):760–764.
   PubMed Web of Science ®Google Scholar
• BIRAGYN A, SURENHU M, YANG D et al.: Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. brimunol. (2001) 167(11):6644–6653.
   Google Scholar
• BIRAGYN A, TANI K, GRIMM MC, WEEKS S, KWAK LW: Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol (1999) 17(3):253–258.
   PubMed Web of Science ®Google Scholar